SIC
BCRX icon

Salem Investment Counselors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Salem Investment Counselors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Hold
200
– – ﹤0.01% 1103
2026
Q1 		$1.9K Buy
+200
New +$1.55K ﹤0.01% 1085
2025
Q4 		– Sell
-200
Closed -$1.52K – 464
2025
Q3 		$1.52K Hold
200
– – ﹤0.01% 1097
2025
Q2 		$1.79K Hold
200
– – ﹤0.01% 1044
2025
Q1 		$1.5K Hold
200
– – ﹤0.01% 1076
2024
Q4 		$1.5K Hold
200
– – ﹤0.01% 1053
2024
Q3 		$1.52K Hold
200
– – ﹤0.01% 1055
2024
Q2 		$1.24K Hold
200
– – ﹤0.01% 1060
2024
Q1 		$1.02K Hold
200
– – ﹤0.01% 1091
2023
Q4 		$1.2K Hold
200
– – ﹤0.01% 1019
2023
Q3 		$1.42K Hold
200
– – ﹤0.01% 1003
2023
Q2 		$1.41K Hold
200
– – ﹤0.01% 1038
2023
Q1 		$1.67K Buy
+200
New +$1.93K ﹤0.01% 995

Other funds holding BCRX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Salem Investment Counselors's BCRX Position: Q2 2026 in Review

Salem Investment Counselors held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 200 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1103.

Salem Investment Counselors first reported a position in BCRX in Q1 2023 and has held it in 13 quarters since. 78 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Salem Investment Counselors held 200 shares of BioCryst Pharmaceuticals worth $2K as of Q2 2026.
  • Salem Investment Counselors left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #1103 holding.
  • Salem Investment Counselors first reported a position in BioCryst Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 78 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.